Waters (WAT), What Is Behind The Fresh Attention?
Waters (WAT) is back in focus after Senior Vice President Robert L. Carpio III resigned from the Waters Analytical Sciences Division, and Tina Wu has stepped into the role following her recent senior leadership experience at DuPont.
See our latest analysis for Waters.
Waters shares trade at US$410.70 after a 10.75% 1 month share price return and 19.96% 3 month share price return. The 1 year total shareholder return of 35.91% contrasts with a modest 0.82% total shareholder return over five years, suggesting momentum has picked up recently as investors reassess the company following leadership changes and other developments through 2026.
If this leadership transition has you thinking about where growth might come from next in markets tied to advanced instrumentation and data, it could be a good moment to scan 21 top founder-led companies
Waters has already moved sharply, yet some investors may still be waiting for a pullback. Is the recent strength after the leadership change stretching the valuation, or does the current price still look reasonable on fundamentals?
Most Popular Narrative: 60% Undervalued
The most followed narrative values Waters at $413.26 per share using an 8.13% discount rate, which sits slightly above the latest $410.70 close. That gap is small in dollar terms, yet the narrative still frames the stock as meaningfully undervalued based on its long term cash flow potential.
Recurring revenues are accelerating (up 11% this quarter), underpinned by expanding service plan attachments and e-commerce adoption, which enhances revenue stability and net margins, setting up the combined company for more resilient earnings across CapEx cycles.
Curious how Waters gets from today’s earnings to that higher valuation? The narrative leans on compound growth, thicker margins, and a future profit multiple usually linked with faster growing sectors. Investors may want to examine which specific revenue and earnings paths are implied.
Result: Fair Value of $413.26 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, you still need to factor in risks for Waters, including potential challenges integrating BD’s Biosciences and Diagnostic Solutions units, as well as pressure from weaker academic and pharma discovery demand.
Find out about the key risks to this Waters narrative.
Another View on Waters Using Sales Multiples
The SWS DCF model points to upside for Waters, yet the sales multiple tells a different story. The stock trades on a P/S of 8.7x, compared with a fair ratio of 7.2x, the US Life Sciences average of 4.5x, and a 5.7x peer average. That richer multiple could mean investors are paying up, so how much margin of safety do you think is left?
For a closer look at how these ratios stack up and what they might imply for future valuation moves, check out the See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
With mixed signals around Waters, it makes sense to look at the underlying data yourself and decide how you feel about the balance of potential risk and reward. To help frame both sides of that debate quickly, walk through the 2 key rewards and 3 important warning signs
Looking for more investment ideas beyond Waters?
If you are serious about building a stronger portfolio, do not stop with Waters. Use targeted stock lists to quickly surface fresh ideas that match your goals.
- Hunt for potential bargains that combine quality with appealing valuations by scanning 48 high quality undervalued stocks.
- Strengthen your income stream by reviewing companies that appear in the 12 dividend fortresses.
- Prioritize resilience and sleep better at night by checking the 78 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com